Upcoming clinical trials
A Phase I/II study to investigate the safety, biologic and anti-tumor activity of oncolytic vaccinia virus armed with a CXCR4 antagonist in combination with pembrolizumab in patients receiving liposomal doxorubicin for recurrent or treatment refractory ovarian, fallopian tube or primary peritoneal cancer (expected mid-2025).
An investigator-initiated lifestyle intervention trial of an automated, personalized physical activity intervention using wearable devices to improve immune function and clinical outcomes in ovarian and endometrial cancer patients (expected early 2025).
View a list of all ovarian cancer clinical trials offered by cancer centers across the United States.